Injection of human growth hormone, also commonly known as growth hormone powder, no preservatives added, injection should be dissolved in sterile water for injection, use a syringe injection. The injection frequency is once a day.
2. Injection
Human growth hormone injection, also commonly referred to as growth hormone water, is available in cassette bottle packaging and pre-potting packaging.
(1) Pre-potting packaging: single single-dose packaging, no preservatives added, direct one-step injection, no need to dispense drugs and replace needles.
(2) Cassette bottle packaging: single multi-dose packaging, add preservatives (mostly phenol), repeated injection, need to use a syringe to extract the liquid injection. [1]
Component editing broadcast
1, injection of human growth hormone:
The main components are human growth hormone and excipient.
2. Human growth hormone injection:
(1) Pre-potting packaging:
Main ingredients: human growth hormone.
Adjuvant: histidine, Poloxam 188, mannitol, water for injection.
(2) Cassette bottle packaging:
Main ingredients: human growth hormone.
Excipients: histidine, Poloxam 188, mannitol, water for injection, glycerin, phenol. [1]
Character editing broadcast
1, injection of human growth hormone:
This product is white freeze-dried powder.
2. Human growth hormone injection:
This product is colorless, transparent liquid. [1]
The indications are edited
1, for the slow growth of children caused by the lack of endogenous growth hormone;
(2) For children with short stature due to Noonan syndrome;
3, for children with short stature or growth disorders caused by SHOX gene deficiency;
4. For children with short stature caused by achondroplasia;
5. For adults with short bowel syndrome receiving nutritional support;
6, for the treatment of severe burns; [1]
Specification editing broadcast
See the instructions for details.
Usage and dosage edit broadcast
Follow the doctor's orders.
Adverse reactions are edited
1. The following information about possible adverse reactions to the use of growth hormone is derived from foreign literature data of similar products, including adverse reactions that occurred in clinical trials and reported in spontaneous post-marketing reports.
(2) Data in clinical trials of foreign growth hormone products: Because clinical trials are conducted under different conditions, the incidence of adverse reactions of a growth hormone preparation often cannot be compared with another growth hormone preparation, and the incidence of adverse reactions cannot reflect the actual clinical use.
3, growth hormone is a protein drug, a few patients will produce antibodies after use. Studies have shown that in patients who have not used growth hormone therapy, a small number of patients have produced growth hormone-specific antibodies after 6 months of growth hormone therapy, but the antibody concentration does not exceed 2mg/L. Long-term injection of recombinant human growth hormone, if antibodies are produced, but the antibody binding force is low, there is no exact clinical significance. However, if the antibody binding force exceeds 2mg/L, the efficacy may be affected. Any patient who does not respond to HGH therapy should be tested for HGH antibodies in addition to assessing their compliance and thyroid function. [1]
Taboo editing broadcast
1. It is forbidden to use for growth-promoting treatment after the epiphysis has been completely closed.
2, serious systemic infection and other critical patients in the body during the acute shock period.
3, known to be allergic to growth hormone or its protective agents prohibited.
4. It is prohibited for patients with active malignant tumors. Any pre-existing malignancies should be inactive and treatment of the tumor should be completed prior to growth hormone therapy. Growth hormone therapy should be discontinued if evidence suggests a risk of tumor recurrence. Since growth hormone deficiency may be an early sign of the presence of pituitary tumors (or other rare brain tumors), the presence of such tumors should be ruled out prior to treatment. Growth hormone should not be used in any patient with potential intracranial tumor progression or recurrence.
5. When complications occur in patients with the following acute critical diseases, it is prohibited: open heart surgery, abdominal surgery or multiple accidental trauma.
6. When acute respiratory failure occurs, it is prohibited.
7. It is prohibited in patients with proliferative or severe non-proliferative diabetic retinopathy.
Note edit broadcast
1, under the guidance of a doctor for the definitive diagnosis of patients.
2. People with diabetes may need to adjust the dose of anti-diabetic drugs.
3, the simultaneous use of corticosteroids will inhibit the growth-promoting effect of growth hormone, so patients with ACTH deficiency should properly adjust the amount of corticosteroids to avoid its inhibitory effect on growth hormone. (See Drug Interactions)
4, a small number of patients in the growth hormone treatment process may occur hypothyroidism, should be corrected in time to avoid affecting the efficacy of growth hormone, so patients should be regularly checked thyroid function, when necessary to give thyroxine supplement.
5. Patients with endocrine disorders (including growth hormone deficiency) may suffer from epiphysis slip of the femoral head, and should pay attention to evaluation if claudication occurs during the treatment period of growth hormone.
6, sometimes growth hormone can lead to excessive insulin state, so it is necessary to pay attention to whether the patient has reduced glucose tolerance phenomenon.
7, During the treatment of blood sugar above 10mmol/L, insulin treatment is required. If more than 150IU/ day of insulin is still unable to effectively control blood sugar, this product should be discontinued.
8, growth hormone to take subcutaneous injection, can be selected around the navel, upper arms, outer thighs, buttocks. The injection of growth hormone needs to change the site frequently to prevent the injection of the same site for a long time to cause the subcutaneous fat atrophy. If the injection is at the same site, it should be noted that the interval of each injection site is more than 2cm.
